KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma

International Journal of Cancer

Volumn 132, Issue 11, 2013, Pages 2502-2509

  Fu, Tao ^a,b   Guzzetta, Angela A ^b   Jeschke, Jana ^b   Vatapalli, Rajita ^b   Dave, Pujan ^b   Hooker, Craig M ^b   Morgan, Richard ^b,c   Iacobuzio Donahue, Christine A ^b,c   Liu, Baohua ^a   Ahuja, Nita ^b,d  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

duodenal adenocarcinoma; KRAS; mutation; prognosis

Indexed keywords

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; DUODENUM CARCINOMA; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; CELL DIFFERENTIATION; DNA, NEOPLASM; DUODENAL NEOPLASMS; FEMALE; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84875601200     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27910     Document Type: Article

References (40)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
2. Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249: 63-71.
3. Halfdanarson TR, McWilliams RR, Donohue JH, et al. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg 2010; 199: 797-803.
4. Macara IG, Lounsbury KM, Richards SA, et al. The Ras superfamily of GTPases. FASEB J 1996; 10: 625-30.
5. Malumbres M, Barbacid M,. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-65.
6. Bos JL,. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9.
7. Karnoub AE, Weinberg RA,. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9: 517-31.
8. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998; 90: 675-84.
9. Younes N, Fulton N, Tanaka R, et al. The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer 1997; 79: 1804-8.
10. Muneyuki T, Watanabe M, Yamanaka M, et al. Combination analysis of genetic alterations and cell proliferation in small intestinal carcinomas. Dig Dis Sci 2000; 45: 2022-8.
11. Rashid A, Hamilton SR,. Genetic alterations in sporadic and Crohn's-associated adenocarcinomas of the small intestine. Gastroenterology 1997; 113: 127-35.
12. Achille A, Baron A, Zamboni G, et al. Molecular pathogenesis of sporadic duodenal cancer. Br J Cancer 1998; 77: 760-5.
13. Yachida S, Mudali S, Martin SA, et al. β-Catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol 2009; 33: 1823-32.
14. Dietmaier W, Wallinger S, Bocker T, et al. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997; 57: 4749-56.
15. Bakaeen FG, Murr MM, Sarr MG, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg 2000; 135: 635-41; discussion 41-2.
16. Lee HG, You DD, Paik KY, et al. Prognostic factors for primary duodenal adenocarcinoma. World J Surg 2008; 32: 2246-52.
17. Joesting DR, Beart RW, Jr, van Heerden JA, et al. Improving survival in adenocarcinoma of the duodenum. Am J Surg 1981; 141: 228-31.
18. Nicholl MB, Ahuja V, Conway WC, et al. Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol 2010; 17: 2728-32.
19. Agrawal S, McCarron EC, Gibbs JF, et al. Surgical management and outcome in primary adenocarcinoma of the small bowel. Ann Surg Oncol 2007; 14: 2263-9.
20. Wu TJ, Yeh CN, Chao TC, et al. Prognostic factors of primary small bowel adenocarcinoma: univariate and multivariate analysis. World J Surg 2006; 30: 391-8; discussion 9.
21. Cunningham JD, Aleali R, Aleali M, et al. Malignant small bowel neoplasms: histopathologic determinants of recurrence and survival. Ann Surg 1997; 225: 300-6.
22. Overman MJ, Hu CY, Wolff RA, et al. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer 2010; 116: 5374-82.
23. Dabaja BS, Suki D, Pro B, et al. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004; 101: 518-26.
24. Abrahams NA, Halverson A, Fazio VW, et al. Adenocarcinoma of the small bowel: a study of 37 cases with emphasis on histologic prognostic factors. Dis Colon Rectum 2002; 45: 1496-502.
25. Thomsen Lonborg J, Vilmar A, Mard D, et al. Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer. Oncol Rep 2007; 18: 1023-9.
26. Gibson MK, Holcroft CA, Kvols LK, et al. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 2005; 10: 132-7.
27. Zaanan A, Gauthier M, Malka D, et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer 2011; 117: 1422-8.
28. Span M, Moerkerk PT, De Goeij AF, et al. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 1996; 69: 241-5.
29. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85: 692-6.
30. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74.
31. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27: 5931-7.
32. Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009; 15: 7322-9.
33. Qiu LX, Mao C, Zhang J, et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 2010; 46: 2781-7.
34. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-9.
35. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
36. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-26.
37. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004; 5: 375-87.
38. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003; 4: 111-20.
39. Choi YL, Moriuchi R, Osawa M, et al. Retroviral expression screening of oncogenes in natural killer cell leukemia. Leuk Res 2005; 29: 943-9.
40. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000; 60: 2368-71.